Abstract Submission Information

If you wish to withdraw an accepted abstract for any reason, you must email your request to abstracts@idsociety.org by the withdrawal deadline. Withdrawal requests MUST come from a listed author to avoid erroneous requests. Withdrawal of an accepted abstract after the withdrawal deadline or failure to present an accepted abstract could result in disqualification from presenting an abstract at IDWeek for the subsequent year. 

Send your withdrawal letter by email to: abstracts@idsociety.org 

Use of AI, Chatbots and Large Language Models 

IDWeek and its partner societies support the World Association of Medical Editors’ recommendations on AI, chatbots and scholarly manuscripts. If AI, a large language model, or a similar tool is used in the development of an abstract submitted to IDWeek, the following is required: 

• The AI/LLM cannot be credited as an author, as authorship requires that the author be accountable for the submitted/published work, and artificial intelligence cannot fulfill this requirement of authorship. 
• Authors listed on the paper must review the content generated by the AI/LLM and take full responsibility for it, as they would for any other content within the submitted/published work. 
• The use of AI/LLM tools must be noted in the abstract. 
• The use of AI/LLM tools must be documented in the Methods, Acknowledgments or another appropriate section of the abstract. 

If reviewers use AI in their evaluation of an abstract, the reviewers must disclose this to each other and to IDWeek staff. Reviewers may not upload an abstract to an AI, LLM or similar system, as this would violate confidentiality. 

Abstracts are considered official communications of the conference. The presenting author and co-authors must comply with the IDWeek embargo policy that abstracts must be based on results that have not been previously published and are not anticipated to be published before the meeting UNLESS the publication occurs AFTER the withdrawal deadline. Abstracts must not be submitted if previously presented at a national or international meeting such as, but not limited to: IDSA, SHEA, ASM, CROI, ASM Microbe or ESCMID. The IDWeek Program Committee will consider abstracts that have been previously submitted at smaller/regional meetings but have not been published in a journal and on the proviso that no rights have previously been transferred; however, all new or updated data must be included in the abstract.

Authors and co-authors transfer any copyrights and agree to release the abstract for future IDWeek publication and grant permission to IDWeek to audio/video record oral presentations for later sale or publication. IDWeek owns the copyrights to all abstracts accepted for presentation in perpetuity. Presenting authors maintain copyrights for their poster and/or presentation slides. In submitting your abstract, you also warrant that you have exercised reasonable care to ensure that the article is accurate and does not contain anything which is libelous, or obscene, or infringes on anyone’s copyright, right of privacy or other rights.

IDWeek regular deadline and late-breaker abstracts are embargoed until Oct. 21 at 12:01 a.m. ET. News releases, media alerts and news materials released in conjunction with IDWeek must be embargoed until the start of the meeting on Oct. 21 at 12:01 a.m. ET, with the exception of research findings presented at IDWeek-sponsored press conferences. Those findings are embargoed until the start of IDWeek or the specific press conference, whichever is later. News releases, media alerts and news materials that contain only abstract titles, author names and affiliated institutions (“curtain raisers”) are permitted in the lead up to IDWeek and may be distributed after abstract titles are released on the IDWeek site on Sept. 1 at 12:01 a.m. ET. View more information in the IDWeek Media Guidelines.

IDWeek abstracts will be published as an online supplement to Open Forum Infectious Diseases, IDSA’s open-access journal. They will be permanently archived as part of the journal and will be accessible to all journal readers, not only meeting attendees or society members. Abstracts will also be available in the IDWeek Interactive Program and in the official IDWeek app for iPhone and Android. If you do not want your abstract included in OFID, the Interactive Program or the app, you must withdraw your abstract completely from the meeting prior to the withdrawal deadline. 

• Authors do not have to be members of one of the sponsoring societies to submit an abstract. 
• Obtain approval in advance from all co-authors before placing their names on the abstract. Submission of an abstract denotes that co-authors as well as authors have read the abstract, take responsibility for its content and approve that their names appear on the abstract. Failure to obtain approval from all authors will result in immediate rejection of the abstract. 
• All authors must agree to the IDWeek embargo and copyright policy. 
• All authors must provide disclosures of potential conflicts of interest and complete an attestation form prior to the submission deadline. List any financial interests, assistance, or relationships with companies, supporters, or commercial products that are related to the research (for example, research support, grants, sponsors, stockholders, etc.). A response to this request must be provided for each author or author group before the abstract can be peer reviewed. IDWeek will not allow or accommodate completion after the submission deadline.
• Adding or removing authors after the submission deadline is not permitted. 

Submitters may return to the online system to edit abstracts; revise information; correct typographical errors, tables and graphics; or delete a submission at any time before the submission deadline. After this time, the system will be closed, and complete abstracts will be reviewed by IDWeek.

An author may not revise or resubmit an abstract to make changes or corrections after the submission deadlines. Adding or removing authors after the submission deadline is not permitted.

Adding or removing authors after the submission deadline is not permitted.

Proofread abstracts carefully to avoid errors before they are submitted. IDWeek is not authorized to make changes to a submission. This includes typographical errors. Your abstract, if selected, will be published exactly as submitted.

Errors in an accepted abstract may be indicated during the presentation.

A request to withdraw an abstract after the submission deadline must be received by IDWeek at abstracts@idsociety.org by the withdrawal date. After this date, withdrawals may still be accepted but abstracts may still appear in publications. Withdrawal of an accepted abstract after the withdrawal date or failure to present an accepted abstract could result in disqualification from presenting an abstract at IDWeek for the subsequent year.

Revisions to your submission can be made before the submission deadline. No changes will be accepted after this deadline. To make changes to your abstract prior to the deadline, follow the link to your submission found in your submission confirmation email. To make a change, select one of the nine steps to submit an abstract and save your changes. You will not receive a new confirmation email. 

Authors can be changed before the submission deadline. Requests after this date will not be accommodated. 

Accepted abstracts can be presented in one of the following presentation types. Please note that all abstract presenters must register to attend IDWeek. Every accepted abstract must be presented by a registered attendee at IDWeek. 

The presenting author is expected to discuss his or her scientific research and summarize the data into a comprehensive 10-minute presentation. Presenting authors are required to use PowerPoint slides to accompany their oral presentations. Oral abstract presenters are required to attend IDWeek in-person.

Poster sessions are abstracts that have been selected and grouped together by category/topics. Poster presentations give authors an opportunity to acquaint attendees and experts in the field with the fundamentals of their abstracts and research. All poster presenters will upload a virtual poster (PDF version) and record a 5-minute audio description for virtual attendees.

• In-Person Poster Presentations (Recommended)
  In-person poster presenters will set up their posters in the poster hall and will be assigned a date and time to present.
• Virtual Poster Presentations
  Virtual poster presenters will upload a virtual poster (PDF version) and record a 5-minute audio description for their presentation. Virtual presenters will not need to be online at their presentation date and time.

Rapid-Fire poster sessions will feature six 5-minute poster presentations from selected presenters and will be presented in the Rapid-Fire arenas in the Poster Hall during lunch. Rapid-Fire poster presenters are required to attend IDWeek in-person.

Use a concise title that summarizes the content of the abstract. Capitalize the first letter of each word except prepositions, articles and species names.  

Select up to two subject categories. View the full list of abstract categories. Abstracts will be divided into categories for review and programming purposes. Please review the entire category list and ensure the correct category is selected for the abstract. 

The IDWeek Program Committee reserves the right to reassign your abstract to a different category if deemed necessary. 

Choose one to three keywords in the menu (highest priority first). Additional keywords are accepted but should be words in common usage, such as those used in Medline and Index Medicus.

Enter complete author(s) names (example: John S. Doe, MD). Include the name, degree, institution, city, state and country of all authors and author groups. Authors cannot be added or removed after the submission deadline has passed. All authors must provide disclosures of potential conflicts of interest and complete an attestation form prior to the submission deadline.

List the name of each author’s institution, city, state and country (do not include department, division, laboratory, etc.). Grant acknowledgments should not appear in abstracts but should be included in the CME disclosures. 

The abstract character limit is 1,950 (spaces are not counted). Title and authors do not count against the 1,950-character limit. Describe the relevance of the research using background, methods, results and conclusions. IDWeek will not edit or revise the abstracts. Submitters/authors are responsible for the accuracy of the abstract text. We recommend that a colleague review the abstract for accuracy and grammar. 

A maximum of four images, figures or tables are permitted for each abstract. There isn’t a maximum allowed resolution for figures. Acceptable file types for images are .gif, .jpg and png. Color images are allowed. Please provide high-resolution images. If the table/image title appears in the images itself, you DO NOT need to enter the title in the title or caption fields as well. Footnotes should be included in the image with table/figure and NOT as another upload. 

Provide all pertinent contact information to ensure that correspondence is received promptly and accurately. You must specify one “presenting author.” IDWeek will correspond with the presenting author using only the contact information that is provided at the time of submission. It is the responsibility of the presenting author to communicate future correspondence to all co-authors. Notifications will be sent to the presenting author only. 

Changes/modifications, including author and affiliation changes, are allowed for submitted abstracts until the abstract submission deadline. Changes to submitted abstracts will not be possible after the submission deadline. Once you submit the abstract, a confirmation message will appear on the screen with an abstract tracking number assigned. Keep a record of your abstract tracking number until you receive your abstract disposition letter. 

A1. Novel agents 

A2. Pharmacokinetics and Pharmacodynamics studies 

A3. Resistance mechanisms 

A4. Treatment of antimicrobial resistant infections 

A5. Pharmacogenetics 

A6. New drug development (formerly L3) 

B1. Studies of correlates of protection (or biomarkers) against microbial infection and disease in patients or experimental models 

B2. Studies of the immune response to microbial infection and disease in patients or experimental models 

B3. Studies of genetic factors that govern susceptibility to microbial infection and disease 

B4. Studies of microbial factors that govern susceptibility to microbial infection and disease 

B5. Studies at the interface of host-microbe interaction 

B6. Microbiome science 

C1. Clinical trials 

C2. Bone and joint 

C3. Skin and soft tissue 

C4. Respiratory infections - viral 

C5. Respiratory infections - bacterial 

C6. Enteric infection 

C7. Bacteremia 

C8. Endocarditis 

C9. CNS infection 

C10. Sexually transmitted infections 

C11. UTIs 

C12. Social determinants of health 

D1. Diagnostics: Bacteriology/mycobacteriology 

D2. Diagnostics: Virology 

D3. Diagnostics: Parasitology 

D4. Diagnostics: Mycology 

D5. Diagnostics: Typing/sequencing 

D6. Diagnostics: New diagnostics (formerly L2) 

D7. Diagnostics: Other (e.g., host response biomarkers, molecular imaging, metabolomics/proteomics, etc.) 

(scholarly work directed at enhancing infectious diseases education of trainees and/or health professionals, social determinants of health)

F1. Hepatitis A 

F2. Hepatitis B 

F3. Hepatitis C 

F4. Hepatitis E 

(e.g., travel medicine, tropical medicine and parasitology, endemic/epidemic diseases of resource-challenged areas, social determinants of health) 

H1. Epidemiology and screening 

H2. Prevention 

H3. Pathogenesis 

H4. Treatment 

H5. Complications and co-infections 

H6. Social determinants of health 

I1. Adult vaccines 

I2. Pediatric vaccines 

I3. Adolescent vaccines 

I4. New vaccines (formerly L3) 

J1. Billing/Coding 

J2. Medical Records & Informatics 

J3. Healthcare Reform 

J4. Home Health/OPAT 

J5. Quality Improvement 

J6. ID Workforce/Value of ID 

J7. Telehealth 

J8. Long Term Care (SNF/LTACH) 

Tuberculosis and Other Mycobacterial Infections 

M1. Clinical studies of fungal infections 

M2. Studies of fungal pathogenesis in patients with immune impairment 

M3. Studies of the pathogenesis of fungal infections 

N1. Health Care-Associated Infections: Occupational infection prevention 

N2. Health Care-Associated Infections: Surveillance 

N3. Health Care-Associated Infections: Epidemiologic methods 

N4. Health Care-Associated Infections: Device-associated (CLABSI, CAUTI, VAP) 

N5. Health Care-Associated Infections: Disinfection/sterilization & environmental infection prevention 

N6. Health Care-Associated Infections: Hand hygiene/transmission-based precautions 

N7. Health Care-Associated Infections: Surgical site infections 

N8. Health Care-Associated Infections: C. difficile 

N9. Health Care-Associated Infections: Gram-positives (MRSA, MSSA, VRE) 

N10. Health Care-Associated Infections: Gram-negatives (MDR-GNR) 

N11. Health Care-Associated Infections: Outbreaks 

N12. Health Care-Associated Infections: Non-acute care 

N13. Health Care-Associated Infections: Non-bacterial (fungal, viral) 

N14. Health Care-Associated Infections: Social determinants of health 

(Studies on issues pertaining to preparedness for and response to outbreaks of infectious diseases including those linked to agents of bioterror, foodborne, waterborne, vector borne, and zoonotic diseases, vaccine-preventable diseases and social determinants of health) 

P1. Pediatric: Bacterial studies (natural history and therapeutic) 

P2. Pediatric: Fungal studies (natural history and therapeutic) 

P3. Pediatric: Viral studies (natural history and therapeutic) 

P4. Pediatric: Antimicrobial stewardship (inpatient/outpatient pediatric focused) 

P5. Pediatric: Health care-associated infection epidemiology and prevention 

P6. Pediatric: HIV 

P7. Pediatric: Maternal-child infections 

P8. Pediatric: Social determinants of health 

S1. Antibiotic stewardship: Program development & evaluation 

S2. Antimicrobial Stewardship: Outcomes assessment (clinical and economic) 

S3. Antibiotic stewardship: Diagnostics/diagnostic stewardship 

S4. Antibiotic stewardship: Special populations 

S5. Antibiotic stewardship: Non-inpatient settings 

S6. Antibiotic stewardship: Trends in antimicrobial prescribing 

S7. Antibiotic stewardship: Social determinants of health 

T1. Studies of pre-transplant screening and evaluation 

T2. Studies of empiric and pre-emptive therapy 

T3. Studies of the epidemiology of infections in transplant patients and patients with impaired immunity due to underlying disease or immunosuppressive drugs 

T4. Social determinants of health 

V1. Studies of the epidemiology of viral infections 

V2. Studies of viral pathogenesis 

V3. Studies of treatment and prevention of viral infections 

Y1. Structural determinants and career advancement (Inclusion, Diversity, Access and Equity) 

Y2. Leadership development 

Y3. Policy and advocacy 

Y4. Ethics, publishing and other academic/professional affairs 

Y5. Structural equity (Inclusion, Diversity, Access and Equity) 

Z1. COVID: Epidemiology and screening 

Z2. COVID: Infection prevention 

Z3. COVID: Pathogenesis 

Z4. COVID: Treatment 

Z5. COVID: Complications, co-infections and clinical outcomes 

Z6. COVID: Diagnostics 

Z7. COVID: Research 

Z8. COVID: Global response/response in low resource settings 

Z9. COVID: Special populations (e.g., pregnant women, children, immunocompromised, etc.) 

Z10. COVID: Impact of social distancing/mitigation measures 

Z11. COVID: Vaccines 

Z12. COVID: Social determinants of health 

Z13. COVID: Other 

Regular Deadline Abstracts

Regular submission opens 

Tuesday, Feb. 17, 2026 

Regular Deadline Abstracts
Submissions close at 11:59 p.m. ET - no changes will be allowed after the deadline

Regular Deadline Abstracts 

Submissions close at 11:59 p.m. ET. No changes will be allowed after the deadline. 

Thursday, April 30, 2026

Late-Breaker Deadline Abstracts 

Late-breaker submission opens 

Monday, June 22, 2026 

Regular Deadline Abstracts 

Regular deadline abstract notifications sent 

Tuesday, June 30, 2026 

Late-Breaker Abstract 

Late-breaker abstract submission deadline 

Tuesday, Aug. 4, 2026 

Regular Deadline Abstracts 

Regular deadline abstract withdrawal deadline 

Friday, Aug. 14, 2026 

IDWeek Abstract Titles

IDWeek abstract regular deadline titles released 

Tuesday, Sept. 1, 2026 

Late-Breaker Abstract

Late-breaker abstract notifications 

Thursday, Sept. 10, 2026 

All Abstracts 

Regular deadline and late-breaker abstract text released to IDWeek registrants 

Tuesday, Oct. 13, 2026 

All Abstracts

IDWeek abstract embargo released 

Wednesday, Oct. 21, 2026 

IDWeek 
Oct. 21-24, 2026 

 View more information about abstract tips & formatting here. 

For technical support with the submission site, please call (direct) (410) 638-9239 or (toll free) (877) 426-6323 between the hours of 9 a.m. and 9 p.m. ET, Monday through Friday, or email Help@ConferenceAbstracts.com.

There is no fee to submit an abstract at this time.

Abstracts must not be submitted if previously presented at a national or international meeting such as, but not limited to: IDSA, SHEA, ASM, CROI, ASM Microbe or ECCMID. Please review the full details of the Embargo and Copyright Policy in the Abstract Policies & Procedures section of this FAQ.

The abstract character limit is 1,950 (spaces are not counted). Title and authors do not count against the 1,950-character limit. Figures are accepted, and they do not count towards the character limit.  

A maximum of four images, figures or tables are permitted for each abstract. There isn’t a maximum allowed resolution for figures. Acceptable file types for images are .gif, .jpg and png. Color images are allowed. Please provide high-resolution images. 

There is no limit to the number of abstracts an author can submit. Do not send multiple submissions of the same abstract. Duplicate abstracts will be rejected. Be sure to combine all new information into one abstract. 

Your submission is complete when you select “Submit” at the end of the abstract submission process. On the screen, you will see the message “Abstract successfully completed.” You will also receive an email with your abstract number and the link to go back and review your submission. Submissions with “Status: INCOMPLETE” cannot be processed. You may update or make changes to your abstract up until the submission deadline.

View all abstract deadlines. Abstract disposition notices will be sent via email to the presenting author only. Abstract dispositions will not be provided over the telephone. It is the responsibility of the presenting author to notify and ensure that all co-authors are informed that the abstract has either been accepted or rejected, and to disseminate the presentation scheduling information. If your abstract is accepted, you will receive guidelines for preparing poster or oral presentations. 

All abstract presenters must register to attend IDWeek. Every accepted abstract must be presented by a registered attendee at IDWeek. 

IDWeek late-breaker abstract submissions are limited to truly late-breaking, high-impact scientific research for which results were not available at the time of the regular abstract submission deadline. Late-breaker abstracts should present data that are high impact, groundbreaking, innovative and newsworthy. IDWeek will accept “non-trial data” abstracts for critical or emerging issues through the call for late breakers. 

Only a very small number of late-breaker abstracts are accepted to IDWeek. 

IDWeek cannot accommodate date/time presentation requests. You may have a listed co-author present your abstract if you are unable to attend and do not wish to withdraw. Please email abstracts@idsociety.org to request to change the presenting author.   

This information will be provided closer to the date of the conference. 

You can find the Embargo and Copyright Policy in the Abstract Policies & Procedures section of this FAQ. 

The following is a suggested style for citing IDWeek abstracts: 

Example Only  
Presenter(s). Title. [Paper/Poster/Talk] presented at IDWeek; October 3-7, 2018; San Francisco, CA. https://idweek.org 

Abstracts from previous IDWeek meetings are available through the Interactive Program for that year and published on the OFID website. In your abstract citation, use the appropriate URL for the meeting in which the abstract was presented. 

Only authors that are listed on the submitted abstract may serve as the presenting author. 

IDWeek only allows for one presenting author. To change the presenting author, a listed author must email abstracts@idsociety.org and provide either the submission ID, poster ID, or title of your abstract and the name of a listed co-author who will serve as the new presenting author. 

If you wish to withdraw an accepted abstract for any reason, you must email your request to abstracts@idsociety.org by the withdrawal deadline. Withdrawal requests MUST come from a listed author to avoid erroneous requests. Withdrawal of an accepted abstract after the withdrawal deadline or failure to present an accepted abstract could result in disqualification from presenting an abstract at IDWeek for the subsequent year. 

Send your withdrawal letter by email to abstracts@idsociety.org.